Navigation Links
STAAR Surgical Reports 19% Revenue Growth Second Quarter
Date:8/2/2011

be profitable in all four quarters of the year, up from our previously stated goal of three," Mr. Caldwell concluded.

Recent Visian Implantable Collamer® Lens (ICL) Highlights

  • Second quarter Visian ICL sales grew 41% to $8.3 million, a new quarterly record.  
  • Sales in our top 10 targeted markets increased 48% in the second quarter with nine of the ten markets posting sales increases in the double digits.   Growth exceeding 48% was experienced in Japan, China, Korea, the United Kingdom, Germany, and India.  
  • The V4b which received CE Mark approval during late 2010 has now been fully implemented in 11 of the 29 markets in which it is approved.  The expanded range of treatments available with this product accounted for a 7% increase in Visian ICL revenues in the markets where it was sold during the quarter.
  • With CE Mark approval for the V4c model of the Visian ICL and Toric ICL in April 2011, the Company initiated its marketing prelaunch plan to introduce the CentraFLOW technology at eight sites in Europe, Saudi Arabia and Argentina.  The plan is to complete implantation in 100 eyes at these sites in order to gain experience helpful for the full launch.  STAAR will execute the full launch of the V4c in countries that accept CE Mark approvals during the third quarter of 2011.  The V4c design provides more comfort for the patient and a more convenient, efficient and cost-effective procedure for both the patient and the surgeon.
  • In addition, the Visian V4 ICL design received regulatory approval in Brazil during June 2011.  The surgical refractive market in Brazil is estimated to be about 92,000 annual refractive procedures by Market Scope.  STAAR plans to launch the Visian V4 ICL in Brazil in the third quarter 2011 and hire direct representation in the Latin America area to work with our distributors.

  • Recent Intraocular Lens (IOL) Highlights'/>"/>

    SOURCE STAAR Surgical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000
    2. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
    3. STAAR Surgical Launches Second Phase of Visian ICL Direct-to-Consumer Advertising Campaign
    4. STAAR Surgical Enters Into Distribution Agreement With Ellex in Australia
    5. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
    6. STAAR Surgicals Visian® ICL Surpasses 200,000 Implants
    7. STAAR Surgical Reports Continued Double Digit Core Revenue Growth
    8. STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
    9. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
    10. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
    11. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... board of directors of Eli Lilly and Company (NYSE: ... of 2015 of $0.50 per share on outstanding common stock. ... to shareholders of record at the close of business on ... is a global healthcare leader that unites caring with discovery ... were founded more than a century ago by a man ...
    (Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
    (Date:5/4/2015)... , May 4, 2015 PharmaEngine, ... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) with ... BAX ) jointly announced that Baxter has submitted ... Medicines Agency (EMA) for MM-398 (irinotecan liposome injection), ... adenocarcinoma of the pancreas who have been previously ...
    Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
    ... 18, 2012  UCB, a leading biopharmaceutical company committed to ... sponsor multiple sets of key epilepsy data at the ... (AAN) in New Orleans from April 21-28.  The data ... drug (AED) Vimpat® (lacosamide) C-V, including updated health-related quality ...
    ... 18, 2012  Sotera Wireless, Inc. announced that it has ... Drug Administration (FDA) for the ViSi Mobile™   System, ... in hospitals. The clearance represents a major milestone in ... system, particularly for ambulatory hospital patients. "Continuous ...
    Cached Medicine Technology:UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 2UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 3UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 4UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 5UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 6UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 7UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 8UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 9Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System 2
    (Date:5/4/2015)... During 2015-2019, the North American probiotic ... the European and APAC probiotic markets are the dominant ... probiotic market lags behind owing to the certain eating ... North American probiotic market is led by the USA ... and Mexico. The North American market for probiotics is ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 HHT is ... for generations. While it can have seemingly mild ... and catastrophic events. Hereditary Hemorrhagic Telangiectasia (HHT) is ... vessels that lack normal capillary connections between an artery ... cause frequent, severe nosebleeds, but may also be present ...
    (Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
    (Date:5/4/2015)... 2015 Getting patients to work with ... is critical to achieving the “triple aim” of better ... this will require a shift in thinking from stakeholders ... health systems move beyond their traditional boundaries to reach ... the third live meeting of the ACO and ...
    (Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
    Breaking Medicine News(10 mins):Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2
    ... by Stanford University researchers found patients with refractory partial ... after deep brain stimulation. This multi-center clinical trial ... nuclei of thalamus for epilepsy (SANTE) persisted and by ... frequency. Full findings of this study are available ...
    ... LEESBURG, Va. , March 17 ... issued a warning to the leadership of the U.S. House ... and pass," "self-executing," or "Slaughter Rule" to enact H.R. 3590, ... been previously approved by the Senate. If this tactic is ...
    ... to Tackle State,s Health Care Crisis & Everything to Make it Worse , ... , , ... ... BOISE, Idaho , March 17 The health ...
    ... SAN FRANCISCO , March 17 For the last year, SEIU officials have been suing 29 local union reformers and whistleblowers who exposed the union,s corruption and backroom deals ... ... ... ...
    ... tends to omit them, report finds , WEDNESDAY, March 17 ... medical studies involving issues of sexual health such as impotence ... "Our study indicates that it,s more prevalent than one might ... which appears in the March 18 issue of the ...
    ... ... for the first time , ... Las Vegas, NV (Vocus) March 17, 2010, , , , ,Calendar Notice, , ,2011 AHR ... , www.ahrexpo.com , , ,WHAT:    ,2011 AHR EXPO® (International Air-Conditioning, Heating, Refrigerating Exposition) , ...
    Cached Medicine News:Health News:Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures 2Health News:Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures 3Health News:Landmark Legal Foundation to File Suit to Stop President's Health Plan if 'Slaughter Rule' is Used 2Health News:Gov. Signs Law Putting Politics Before Patients 2Health News:Gov. Signs Law Putting Politics Before Patients 3Health News:Democracy on Trial: SEIU's $25 Million Lawsuit Against Union Reformers Goes to Court Monday 2Health News:Democracy on Trial: SEIU's $25 Million Lawsuit Against Union Reformers Goes to Court Monday 3Health News:Gays, Lesbians Excluded From Some Medical Studies 2Health News:2011 AHR EXPO Calendar Listing 2Health News:2011 AHR EXPO Calendar Listing 3Health News:2011 AHR EXPO Calendar Listing 4
    ... all Gilson disposable pipette tips, ... sterilized version. Each Sterilized TowerPack ... device-quality plastic to help protect ... guaranteed by the red sticker, ...
    Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
    ... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
    Inquire...
    Medicine Products: